INTRODUCTION

Meningococcal infections; historical background
Epidemic cerebrospinal fever and rapid lethal septicemia with hemorrhagic spots have been known as a clinical entity since Vieusseux described both clinical presentations in 1805. 1 Weichelbaum identified the Gram-negative Diplococcus intracellulare, later known as Neisseria meningitidis, to be the cause of epidemic cerebrospinal fever in 1887. 2 In 1906, Andrewes discovered that meningococci may cause single cases of acute fatal septicemia with purpuric spots and hemorrhagic destruction of the adrenals. His patient, a physician, lacked signs of meningitis. 3 This clinical presentation was later known as Waterhouse Friderichsen's syndrome. 4, 5 N. meningitidis attacked primarily infants, children, and recruits entering the military service. The number of cases peaked during the winter and early spring. The same epidemiological pattern is present today in temperate climate zones.
Endotoxin, initially known as a heat-resistant, bacterial cell wall constituent with toxic properties, was regarded as the main toxic principle harbored by N. meningitidis. [6] [7] [8] The lethal effect could be neutralized with antisera obtained from immunized rabbits and horses. [6] [7] [8] Within a few years, intravenous and intrathecal (injection into the spinal canal) therapy with anti-meningococcal horse serum was used world-wide. 9, 10 Serum therapy reduced the case fatality rate from ~80% to 35-40% and was used on a large scale until the 1930s. 10 The introduction of sulfonamides in the late 1930s and benzylpenicillin in the mid 1940s lowered the average mortality to approximately 10% in industrialized countries, a level which has remained unchanged until today.
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asymptomatically by approximately 10% of the population in industrialized countries. [11] [12] [13] [14] Most carried strains never cause disease. [11] [12] [13] [14] In closed communities with young people and during epidemics, the carriage rate can be much higher. 13 Strains belonging to a few clonal complexes cause the majority of clinical cases. 11 Even carriers of pathogenic strains rarely develop invasive infections. [11] [12] [13] [14] Meningococci are transferred from person to person by droplets, colonize the nasopharyngeal mucosa, penetrate the mucosal barrier, and gain access to the circulation. 15, 16 Depending on the host's immune defense, different clinical scenarios may develop. Most intruding meningococci are presumably immediately killed, and the infection is aborted. Meningococci that are able to survive and proliferate in the circulation cause bacteremia and clinical disease. 17 If the meningococci multiply rapidly and produce large quantities of outer membrane material, the patients develop septicemia and shock. [17] [18] [19] [20] More slowly dividing meningococci cause mild meningococcemia. [17] [18] [19] [20] In the majority of cases, they cause bacteremia and subsequently seed the meninges and cause meningitis. [17] [18] [19] [20] The highly variable interplay between meningococci and the host is presently not well understood.
Fulminant meningococcal septicemia
The most feared clinical presentation is fulminant septicemia without overt signs of meningitis. It occurs in 20-30% of cases caused by serogroup B and C strains. These patients develop life-threatening symptoms within 8-16 h. The symptoms are circulatory collapse, renal and pulmonary failure, severe coagulopathy, and thrombosis leading to skin necrosis and gangrene of the peripheral extremities. 12, [19] [20] [21] [22] [23] Untreated, the mortality is 100%. With modern intensive care treatment, the case fatality rate is in the range of 20-50%.
Distinct meningococcal meningitis
The most common presentation (> 50% of all cases) is meningococcemia and subsequently meningitis leading to nuchal and spinal rigidity, altered consciousness, and if untreated, coma and death. Hemodynamic, renal, and pulmonary function are not severely affected. 12, [19] [20] [21] [22] [23] With adequate antibiotic treatment, the case fatality rate is low (≤5%). Deafness is the most common severe complication.
Distinct meningitis and persistent septic shock/fulminant septicemia
The patient has marked symptoms of meningitis and a severely impaired circulation. The mortality is lower than observed in patients with fulminant septicemia but higher than for patients with meningitis. 12, [19] [20] [21] [22] [23] 
Mild meningococcemia
Mild meningococcemia (10-20% of all cases) without distinct meningitis occurs if the bacteremia is contained at a low level by the host's immune system or if the patient is treated early with antibiotics. 12, [19] [20] [21] [22] [23] These patients do not develop distinct meningitis or septic shock, and there is no mortality.
Known predisposing conditions, the different clinical presentations, and the underlying pathophysiology have recently been reviewed by several authors. 12, [19] [20] [21] [22] [23] [24] [25] 
INFLAMMATION INDUCING COMPONENTS OF N. MENINGITIDIS
Inflammatory properties of the outer membrane
The outer membrane of meningococci harbors lipopolysaccharides (LPSs), proteins, and peptidoglycan; each has inflammation-inducing properties. [26] [27] [28] [29] [30] LPSs appear to be the most potent of these molecules. [26] [27] [28] [29] [30] LPSs are abundantly present in the outer leaflet of the outer membrane and are shed in outer membrane vesicles (blebs). [31] [32] [33] Based on the 2-keto-3-deoxy-octulosonic acid (KDO) content, the number of LPS molecules has been calculated to be 1.5 x 10 5 per bacterium for the reference strain 44/76 (B:15:P1.7, 16:L3, 7, 9) . 26 The LPS content of the outer membrane of strain 44/76 is approximately 50% of the protein content on a weight/weight basis. 34, 35 Based on the molecular masses of LPS which is 3.5-4.2 kDa in N. meningitidis 44/76, and the two major outer membrane porins (PorA [42 kDa] and PorB [37 kDa]) that account for more than 70% of the outer membrane proteins, there are approximately 5-6 times more molecules of LPS than proteins in the meningococcal outer membrane. 34 
Secretory IgA protease
Secretory IgA protease derived from pathogenic Neisseria has the capacity to induce pro-inflammatory cytokines in vitro. 36 The role of this protease during invasive disease is presently unknown. Recently conducted in vitro experiments with plasma collected from patients with fulminant meningococcal septicemia suggest that the main inflammation-inducing component is not secretory IgA protease. 37
THE N. MENINGITIDIS MUTANT LACKING LPS
N. meningitidis is the first Gram-negative bacterium to be successfully transformed by targeted mutagenesis to a mutant completely lacking LPS (H44/76 lpxA -). 38 Comparison between the parent strain (H44/76) and the mutant (H44/76 lpxA -) has conclusively documented that the outer membrane contains other inflammationinducing principles than LPS. [26] [27] [28] [29] [30] The mutant H44/76 lpxAactivates human monocytes, peripheral blood mononuclear cells and dendritic cells. [26] [27] [28] [29] [30] However, 10-100-fold more mutant bacteria are required to induce the same level of newly synthesized TNF-α in cell model systems. [26] [27] [28] Interferon-γ (IFN-γ) production in peripheral blood mononuclear cells was primarily stimulated by non-LPS bacterial constituents. 30 Maximum dendritic cell activation and IL-12 production required LPS expression in intact bacteria. 29 The cell-activating property of H44/76 lpxAis primarily attributable to membrane-associated proteins signaling through the CD14-Toll-like receptor 2 (TLR-2) pathway. 27, 28 The relative contribution of meningococcal peptidoglycan to cell stimulation, which is thought to be mediated through the CD14-Toll 2 pathway, remains to be elucidated. At concentrations of more than 10 7 meningococci/ml, the non-LPS constituents of N. meningitidis may contribute significantly to the inflammatory reaction of the host. 27, 29, 30 
OUTER MEMBRANE VESICLES DEPLETED OF LPS
In vitro studies using LPS-depleted outer membrane vesicles support the results obtained with the LPS-defective N. meningitidis mutants. The LPS content in the vaccine blebs is reduced by deoxycholate treatment to approximately 10% of the content in meningococcal outer membrane. 34, 35 The remaining LPS molecules are presumably tightly associated with outer membrane porins. 39 High concentrations of the Norwegian vaccine blebs (LPS concentration, 1 µg/ml) activate human whole blood to produce inflammatory cytokines. 40 The same results were obtained with 5 µg/ml of the Cuban LPS-reduced outer membrane vesicles vaccine using human neutrophils as target cells. 41 However, if one uses many fewer outer membrane vesicles, with concentrations of LPS that correspond to levels (500-5000 pg/ml) commonly detected in the blood or cerebrospinal fluid (CSF) of patients, the results are different. 35 Native outer membrane vesicles stimulate human monocytes to release pro-inflammatory cytokines in a dosedependent manner. 35 If the same concentrations of LPS are used in LPS-depleted (10% of normal LPS content) vaccine blebs, the human monocytes remain inactive. 35 The remaining LPS molecules in the porin-LPS complexes in the vaccine blebs, may be so tightly bound that they are unable to translocate from the outer membrane to LPS-binding protein (LBP) and associate with CD14 on target cells. 35, 39 The other CD14 reactive molecules (proteins, peptidoglycan) in the vaccine vesicles are apparently of lower biological potency and are unable to activate the monocytes at the concentrations tested. 35 Higher concentrations (10-100fold) of the vaccine blebs are required to activate the target cells (Bjerre A, unpublished data). Together, these results indicate that different molecules in the cell wall of N. meningitidis may activate blood cells and macrophages. LPSs are abundantly present and appear to be biologically the most active.
TOXICITY OF N. MENINGITIDIS LPS
When rabbits are given 10 µg/kg purified N. meningitidis LPS intravenously, 90% die within 24 h. 42 Pretreatment with the Limulus antilipopolysaccharide factor, a lipid A neutralizing protein of 11.8 kDa found in Limulus polyphemus amebocytes, reduces the mortality to 8%. 42 These experiments indicate that lipid A is the toxic center of meningococcal LPS. Interestingly, polymyxin B did not protect rabbits from the toxic effects of meningococcal LPS. 43 Previously, polymyxin B was shown to be unable to block the secretion of IL-1β from human monocytes when stimulated by N. meningitidis LPS, whereas it effectively blocked the effect of LPS derived from various other Gram-negative bacteria. 44 The toxicity of purified N. meningitidis LPS can be significantly reduced by incorporating the molecules into liposomes. 45 LPSs from different strains vary in the ability to activate the Limulus amebocyte lysate (LAL) assay suggesting structural heterogeneity of lipid A between strains. 46 The toxicity of outer membrane vesicles Native meningococcal blebs are potent activators of human monocytes and whole blood, and are even more potent than purified meningococcal LPS in activating the LAL assay. 35 Outer membrane vesicles produced from the N. meningitidis serogroup B (H44/76) strain and infused intravenously for 1 h induced 37.5% and 44% mortality in young piglets and older pigs, respectively. 47
THE CHEMISTRY OF N. MENINGITIDIS LPS
N. meningitidis LPS consists of lipid A, a core structure containing two 2-keto-3-deoxy-octulosonic acid (KDO) and two heptoses (L-glycero-D-manno-heptopyranoside) substituted with short polysaccharide side chains ( Fig.  1 ). [48] [49] [50] Owing to the short polysaccharide side chains and lack of repeating O antigen units, meningococcal LPS is often referred to as lipo-oligosaccharide (LOS). The genetic basis for synthesis, structure, and function of meningococcal LPS has recently been thoroughly reviewed. 50 
Oligosaccharide side chain
The centrally located KDO, to which a second KDO is attached, connects lipid A and the first heptose (α-chain). A second heptose (β-chain heptose) is connected to the first heptose. 51, 52 The variable substitution of the first and second heptose accounts for 11 different immunotypes (Fig. 2) . [51] [52] [53] [54] The terminal four-sugar moiety lacto-N-neotetraose (Galβ1→4GlcNAcβ1-3Galβ1→4Glc) is detected in immunotypes L2, L3, L5, L7 and L9. 55, 56 Lacto-N-neotetraose is the acceptor site of N-acetyl-neuraminic acid (NANA; sialic acid). Sialylation of lacto-N-neotetraose may increase the serum resistance of meningococci through down-regulating alternative complement pathway activation. 55, 57 However, recent experiments employing the infant rat model suggest that sialylation of lacto-N-neotetraose is of minor importance for resistance to invasive strains of serogroup B (ET 5 complex) and C (ET-37 complex). 58 Sialylation of LPS may reduce the ability of pathogenic Neisseria to invade host cells. 16, 59 Lacto-N-neotetraose strongly inhibits the binding of mannan-binding lectin (MBL) to meningococcal LPS. 60 MBL is a plasma protein which functions as an opsonin and may activate the classical pathway of complement without the presence of antibodies. 61 Low plasma levels of MBL have been associated with increased risk of contracting meningococcal infections in children. 62 Lipid A as the toxic center of N. meningitidis LPS Lipid A is the toxic moiety of LPS through its ability to upregulate inflammation mediators. 63, 64 Changes in the normal configuration of lipid A reduce the biological potency. This has conclusively been shown for meningococcal lipid A. If N. meningitidis LPS is treated with acyloxacyl hydrolase, a leukocyte enzyme that selectively removes the secondary acyl chains from lipid A, the biological potency (i.e. the ability to activate the LAL assay and to stimulate neutrophils to adhere to endothelial cells) is reduced 30-100fold. 65 The potency of deacylated meningococcal LPS in the murine splenocyte mitogenicity test was reduced over 100-fold. 65 This reduction was much more pronounced than for deacylated lipid A derived from Escherichia coli, Haemophilus influenzae, Pseudomonas aeruginosa and Salmonella typhimurium which was less than 15-fold. 65 Acyloxacyl hydrolase plays an important role in detoxifying lipid A of phagocytosed Gram-negative bacteria. 66, 67 In an elegant series of experiments performed by the vaccine group at the National Institute of Public Health and Environment in The Netherlands, the synthesis of lipid A of the reference strain N. meningitidis (H44/76) has been systematically manipulated by targeted mutagenesis and insertion of enzymes from other bacteria that are required for lipid A synthesis. Strains with penta-acylated and tetraacylated lipid A have a 100-fold reduced toxicity as measured by synthesis of TNF-α in a human macrophage cell line (MM6 cells). 68 Interestingly, the penta-acyl lipid A with the remaining acyloxacyl chain in the reducing end of the molecule retains its adjuvant activity, whereas the adjuvant activity of the tetra-acylated lipid A lacking both secondary lauroyl chains is strongly reduced. 68 By replacing the lpxA gene of N. meningitidis H44/76 by the E. coli or P. aeruginosa homologs, the majority of the O-linked 3-OH-C12 in N. meningitidis is replaced by 3-OH-C14 (from E. coli strain HA01E) or 3-OH-C10 (from P. aeruginosa strain HA25P). Both LPSs with altered lipid A structures are 10-fold less potent in their ability to induce TNF-α secretion of MM6 cells than is the wild-type strain. 69 Molecular mimicry of N. meningitidis LPS Lacto-N-neotetraose located on the surface of pathogenic Neisseria is immunologically identical to the glycosphingolipid paragloboside on mammalian cells. 70 The trisaccharide galactose-glucosamine-galactose is also present in pathogenic Neisseria. 53, 70 Immunologically identical structures detected abundantly on the surface of meningococci and human cells are considered to represent molecular mimicry. They are supposed to play an important role in the lack of immune recognition as foreign molecules by the host, particularly when the non-reducing end is sialylated. 53, 70, 71 
N. MENINGITIDIS LPS STRUCTURES AND IMMUNOTYPES
The chemical structure
The chemical structures of the majority of the immunotypes have been elucidated. [72] [73] [74] [75] [76] [77] [78] [79] Heterogeneity of the LPS purified from a single strain is commonly observed and may be related to growth conditions. 50, 71, [80] [81] [82] This is caused by variable substitution of NANA, sugars with phosphoethanolamine and variable sugar substitution of the first and second heptoses. 53 
N. meningitidis LPS immunotypes and clinical disease
Scholten et al. studied 425 serogroup B isolates systematically collected in The Netherlands during 1989-1990, using whole cell ELISA and a panel of monoclonal antibodies. 83 The distribution of the different immunotypes is seen in Table 1 . One strain may express several immunotypes, although one immunotype is usually dominant.
Based on these results and knowledge of the chemical structures of the various immunotypes, they distinguished two main categories of related immunotypes among invasive serogroup B and C isolates: category 1 -L1, L3, L7, L9, L8; and category 2 -L2, L4. Immunotypes of one category were detected together but rarely, if ever, combined with immunotypes from the second category (Table 1) . 83 Immunotypes L3, L7 and L9 were associated with invasive disease in 80% of the isolates, whereas L8 was expressed more prominently among carriers in one study from the UK. 84 The shorter L8 is more sensitive to serum bactericidal activity than are the longer L3, L7, and L9. 85 Phase variation of LPS occurs frequently. Rapid switching of surface molecules is presumably a prerequisite for meningococci to be able to pass from the surface of the nasopharyngeal epithelium into the circulation and subarachnoid space. 15, 16, 86 The genetic basis for these rapid changes is now understood since the complete genomes of N. meningitidis serogroup A and B have been sequenced and published. 87, 88 Furthermore, we have a more thorough knowledge of the synthesis of meningococcal LPS. 50, 53, 86 PHYSICOCHEMICAL CHARACTERISTICS
OF N. MENINGITIDIS LPS
Purified N. meningitidis LPS and cell activation
Purified meningococcal LPS forms large complexes in aqueous solution. 89 In cells expressing CD14 (monocytes, macrophages, neutrophils), larger LPS aggregates appear to have lower cell-activating potency than smaller sized aggregates. The capsule polysaccharide does not affect the activation of these cells. 89 In endothelial cells, which are dependent on soluble CD14 for LPS-induced activation, the size of the aggregates does not influence cell activation, whereas capsular polysaccharide reduces the activation. 89 
In vitro studies of N. meningitidis LPS in outer membrane vesicles
Outer membrane vesicles produced by N. meningitidis induce dose-dependent production of cytokines (TNF-α, IL-6) and tissue factor in human monocytes and in a whole blood model. 35 The biological activity of the outer membrane vesicles was close to that induced by purified N. meningitidis LPS. Antibodies blocking CD14 reduced the monocyte activation induced by the blebs to < 5%. 35 The outer membrane vesicles were more potent than purified N. meningitidis in activating the Limulus coagulation cascade. 35 
Physicochemical characteristics of LPS in plasma or CSF of patients
In patients, meningococcal LPS is present as whole bacteria, fragments due to lysis, or outer membrane vesicles released during growth. Outer membrane vesicles and fragments of meningoccci with 'spaghetti-like' structures have been visualized in CSF and plasma collected from patients. 32, 33 Ultracentrifugation studies of patient plasma containing native meningococcal LPS indicate that the biological activity as measured by LAL is present as large aggregates. 33 
QUANTIFICATION OF LPS IN PLASMA
AND CSF OF PATIENTS
The Limulus amebocyte lysate (LAL) assay of clinical specimens LAL combined with a chromogenic substrate has been crucial for elucidating the quantitative association between meningococcal LPS and clinical disease. In the 1980s and 1990s, several groups reported that patients with meningococcal infections who developed circulatory collapse, multiple organ failure, and massive coagulopathy had exceptionally high levels of LPS in the circulation when compared with patients with other types of Gram-negative sepsis. 18, 20, [90] [91] [92] [93] To optimize measurements of LPS in plasma, one should collect blood in LPS-free heparinized vacuum tubes, standardize centrifugation (1400 g for 10 min), and store at -20°C in LPS-free cryotubes until analyzed. 18, 94 All measurements performed by our group have been related to the bioactivity of E. coli O55:B5 LPS (100 pg/ml = 0.7-1.0 endotoxin units/ml [EU/ml]), as reference endotoxin. 18, 94 
EXPERIMENTAL ENDOTOXINEMIA IN MAN
The biological effects of purified LPS given as a bolus injection to healthy volunteers have been extensively 83 Serogroup n  L3  L3,L8  L1,L8  L2  L8  L3,L1  L4  L3,L1,L8  Non-typable   B  425  36  28  11  10  5  4  4  2  0  C  104  37  7  0  30  3  1  15  3  3 studied over the last 20 years and have recently been reviewed. 95
N. MENINGITIDIS LPS AND CLINICAL PRESENTATIONS
The levels of LPS in plasma are closely correlated with the development of septic shock, renal impairment, pulmonary edema (acute respiratory distress syndrome, ARDS), massive coagulopathy, and a fatal outcome. 18, 20, 92, 93, 96 Plasma levels > 7 EU/ml (700 pg E. coli O55:B5 LPS/ml) are associated with the development of persistent septic shock (Table 2) . 18, 20 The majority of the patients have plasma levels of LPS < 7 EU/ml and do not develop severe organ complications. 18, 20 As an exception, we have recently identified one child with distinct meningitis without severe circulatory impairment who had an initial plasma LPS concentration of 19 EU/ml, a level that previously always has been associated with persistent septic shock. Observation of this single patient suggests that occasionally humans may tolerate significantly higher levels of LPS in the blood without developing serious circulatory complications (Brandtzaeg P, unpublished data).
Plasma LPS levels and death related to circulatory collapse
In subsequently studied patients with meningococcal infections, we have found a consistent association between maximum plasma levels of LPS and the case fatality rate. 18 20, 92, 96 However, quantitative measurements of meningococcal LPS and inflammatory mediators document that the bacterial growth is not evenly distributed between the vascular and the subarachnoid compartments. 18, 20, 92, 96 Furthermore, LPS levels indicate that the clinical symptoms are closely associated with the levels of LPS in the different compartments. 12, 20, 92, 93, 96 Neisseria meningitidis LPSs in human pathology 407 The LPS levels in all samples were determined with the LAL assay using E. coli LPS O55:B5 as standard (100 pg/ml = 0.7-1.0 endotoxin unit/ml). *The first heparinized plasma for LAL assay was collected 10 h after initiation of antibiotic therapy.
Compartmentalized LPS production in fulminant meningococcal septicemia
The LPS concentrations are 100-1000 times higher in plasma than in CSF in patients with fulminant meningococcal septicemia. 18, 20, 92, 96 In a series of 90 patients with meningococcal infection, 32 patients developed fulminant septicemia of whom 16 died. The median LPS level was 31 EU/ml in these patients, whereas the median was < 0.25 EU/ml in 58 patients with meningitis or mild meningococcemia. 20 Non-surviving patients with fulminant septicemia had a median initial plasma LPS level of 110 EU/ml; this differed significantly from the median initial LPS level of 17 EU/ml in survivors. 20 The median level of LPS in CSF was 0.4 EU/ml among 7 patients with fulminant septicemia who underwent spinal puncture. 20
Compartmentalized LPS production in meningococcal meningitis
In patients with meningitis, bacterial proliferation occurs primarily in the CSF, and the median LPS level in CSF is 1000-fold higher than in plasma. 20.92 Levels of LPS > 8 EU/ml correlated positively with neutrophil counts ≥10 9 /l in CSF. 92 The protein levels in CSF correlated positively with LPS levels, whereas the ratio of glucose in CSF versus serum correlated negatively with the LPS levels. 92 
LPS levels in patients with mild meningococcemia who lack clinical signs of meningitis
Patients with mild meningococcemia without shock and distinct meningitis have plasma LPS levels ≤6 EU/ml and low levels of LPS in CSF. 20 However, one of our patients revealed a high level of LPS in CSF but lacked significant pleocytosis and clinical symptoms of meningitis. 92 The influx of neutrophils to the subarachnoid space may have been differently regulated in this young man as compared with the majority of patients developing distinct clinical signs of meningitis and massive pleocytosis.
ANTIBIOTICS AND LIBERATION OF N. MENINGITIDIS LPS
Model studies of antibiotic induced N. meningitidis LPS release
In vitro studies suggest that the levels of cell-free endotoxin are lower in cultures of antibiotic-treated strains than cultures of untreated strains. 97 If live meningococci are added to whole blood and cytokine release into the plasma is used as an indication of cell activation, effective antibiotic treatment results in lower cytokine levels as compared with untreated controls. 97 In a model system employing human umbilical vein endothelial cells (HUVEC) and various strains of N. meningitidis, treatment with penicillin or gentamicin resulted in lower levels of HUVEC tissue factor expression than was found in untreated controls. 98 Effective antibiotic treatment in these model systems stops bacterial growth and LPS production. Antibiotic treatment does not lead to increased LPS release that augments cell activation compared with untreated controls where LPS production continues. These in vitro studies do not support the concern that antibiotic treatment may precipitate a burst of LPS release that induces septic shock.
Elimination of native N. meningitidis LPS from the circulation in patients
After the first injection of an appropriate antibiotic, plasma levels of meningococcal LPS immediately decline. 18 LPS is eliminated with a half-life of 1-3 h during the first 6 h after antibiotic therapy is initiated. 18 Later, the half-life increases to 4-9 h varying from patient to patient. 18 Consequently, blood samples collected a few hours after the first injection of antibiotics reveal only a fraction of the maximum level of plasma LPS. 18 Among more than 100 patients with meningococcal infection studied by testing serially collected plasma samples, we have never observed increasing plasma levels of LPS as a consequence of cell wall destabilizing antibiotics such as benzylpenicillin (Brandtzaeg P, unpublished results).
The effect of antibiotics on the plasma levels of inflammatory mediators
A variety of inflammatory mediators decline in parallel with the declining levels of plasma LPS in patients with meningococcal infections (see later). The cells producing these inflammatory mediators appear to 'sense' decreasing levels of LPS and immediately down-regulate mediator production. The interaction between LPSresponsive cells and increasing and decreasing plasma levels of LPS appears to be tightly regulated in man. These regulating systems are apparently not out of control even in desperately ill patients.
LPS AND INFLAMMATORY MEDIATORS
LPS, cytokines, and plasma cascade systems
The quantitative differences of LPS levels in the circulation or CSF are reflected in major inflammatory cytokines. 12, 17, 19, 96 Furthermore, the levels of LPS in the circulation are associated with the activation state of the coagulation, complement, and kallikrein-kinin systems as well as inhibition of the fibrinolytic system. 12, 17 Tumor necrosis factor-α TNF-α is released during experimental human endotoxinemia peaking 2 h after bolus injection of E. coli LPS. 99 The levels of bioactive TNF-α are closely associated with the levels of N. meningitidis LPS in plasma and CSF. 100, 101 Biologically active TNF-α is regularly detectable in plasma or serum in patients with LPS levels > 7 EU/ml, 'shock threshold level' but are seldom observed in patients with LPS levels < 7 EU/ml. 102 Biologically active TNF-α positively correlated with plasma LPS in 11 patients with meningococcal infections (Table 4 ). 102 The relationship between TNF-α and disease severity has been confirmed by others. 93, 103, 104 Soluble tumor necrosis factor receptors p55 and p75
The biological activity of TNF-α is antagonized by the release of soluble TNF receptors (sTNFR-p55 and sTNFR-p75). Both types of TNF-receptors are released into the circulation and CSF in patients with meningococcal infections. 93, 105 The release pattern of sTNFRs is compartmentalized and associated with TNF-α levels. 93 Patients with fulminant sepsis, with high levels of LPS and TNF-α in the circulation, had high levels of sTNFR-p55 and sTNFR-p75 in plasma and low levels in CSF, whereas the opposite pattern was observed in patients with distinct meningitis without shock. 93 In patients with persistent meningococcal septic shock, sTNFR-p55 increased more than sTNFR-p75 indicating different release patterns for the two receptors. 93 The levels in plasma and CSF declined quickly following antibiotic therapy. 93, 105 Thus, the release of TNFRs appears to be closely associated with the plasma and CSF levels of TNF-α and LPS.
Tumor necrosis factor-β TNF-β was not detected in any of 79 serum samples collected from patients with meningococcal infections tested in a cell assay. 100
Interleukin-1β
IL-1β is detectable at low levels in experimentally induced human endotoxinemia. 106 IL-β is compartmentalized in meningococcal infections. Patients with fulminant meningococcal septicemia and very high levels of plasma LPS have increased levels of IL-1β in plasma and low levels in CSF. 93, 103, 107 Patients with meningitis reveal high levels in CSF and low levels in plasma. 93, 103, 107 Animal experiments indicate that the toxic effect of TNF-α and IL-β increases synergistically when combined. 108 Bioactive IL-1, as evaluated by the ability to induce IL-2 secretion in LBRM-33-1A5 cells, was detected in only three of eight patients with severe septic shock. 100 These patients had very high initial plasma levels of native LPS > 120 EU/ml. 100 Bioactive IL-1 was detected in CSF in 50% of the patients with meningitis but not in plasma. 101 Interleukin-1 receptor antagonist IL-1 receptor antagonist (IL-1Ra) is released during experimental endotoxinemia in man. 106 The levels of IL-1Ra are 100-fold higher than those of IL-1β. 106 It modulates, together with IL-1 receptor II (sIL-1R-II), the biological activity of IL-1β and has, by itself, no agonistic activity. The release of IL-1Ra is compartmentalized in meningococcal infections. 107 Patients with meningococcal septic shock without distinct meningitis reveal high levels in the circulation and low levels in the subarachnoid space. 107 The opposite pattern is present in patients with meningitis. 107
Soluble interleukin-1-receptor II
Interleukin-1-receptor II (IL-1R-II) is a 'decoy receptor' lacking the capacity to activate cells. The plasma levels do not increase in healthy volunteers challenged with E. coli Neisseria meningitidis LPSs in human pathology 409 LPS and followed for 6 h. 109 Circulating IL-1R-II (sIL-1R-II) levels do not differ significantly between patients with fulminant meningococcal septicemia or meningitis, i.e. patients with high and low levels of LPS. 107 sIL-1R-II levels increase gradually in plasma in all clinical presentations reaching maximum values 70-100 h after initiation of treatment. 107 The median level is 10 times higher in CSF in patients with meningitis compared with patients with septic shock indicating that the release of sIL-1R-II is partly compartmentalized. 107
Interleukin-2
IL-2 is a potent lymphocyte activator. IL-2 levels were determined in a cell bio-assay in 79 patients with meningococcal infections. None had detectable levels. 100
Interleukin-4
IL-4 has anti-inflammatory properties and decreases monocyte reactivity. 110 It was not detected in plasma from patients with meningococcal septic shock screened for monocyte deactivating components. 111 It does not appear to play an important role in the cytokine network elicited by meningococcal LPS.
Interleukin-6
Bolus injections of E. coli endotoxin in man elicit IL-6 secretion to the circulation. 112 In patients with meningococcal infections, plasma and CSF levels are closely associated with levels of LPS and clinical presentation (Table 4) . 100 ,101,105,113 IL-6 is up-regulated 1000-100,000 times in plasma in patients with rapidly fatal meningococcal septic shock. 100 Using a bio-assay, levels ≥10 ng/ml were closely associated with the development of septic shock. 100 The plasma levels decline rapidly after initiation of antibiotic treatment in parallel with TNF-α and IL-1β levels. 100, 113 IL-6 is not considered to be a 'toxic' cytokine and does not directly contribute to septic shock. The quantitative association between IL-6 and fatal septic shock appears to be indirect. IL-6 is one of many inflammatory mediators elicited by LPS and is generated simultaneously with other pro-and antiinflammatory cytokines in meningococcal infections. 12, 17 IL-6 is a potent inducer of the 'acute phase response' in hepatocytes that contributes to host defense.
Soluble interleukin-6 receptor (sIL-6R)
The levels of sIL-6R in plasma are inversely correlated to the levels of circulating IL-6 on admission. 113 Whereas IL-6 levels decline rapidly after initiation of treatment, sIL-6R increases. It reaches peak levels 90-120 h after initiation of treatment in surviving patients. 113 Interleukin-8 IL-8 is released during experimental E. coli endotoxinemia in healthy volunteers. 114, 115 High levels are present in the circulation of patients with fulminant meningococcal septicemia, whereas patients with low-grade meningococcemia (i.e. patients with mild systemic meningococcemia) and patients with meningitis (non-shock patients) have much lower plasma levels. 116 In CSF, the pattern of release is different. Patients with meningitis and high levels of LPS in CSF have the same levels of IL-8 as do patients who present without signs of distinct meningitis and low or undetectable levels of LPS. 116 Plasma levels of IL-8 decrease rapidly in the circulation after initiation of antibiotic therapy, closely following the kinetics of TNF-α and IL-6. 116 Interleukin-10 IL-10 peaks in plasma 3 h after the bolus injection of E. coli in man. 109 IL-10 has strong anti-inflammatory properties and down-regulates cell activation induced by LPS. It has a protective role in LPS-induced shock. 117 In patients with meningococcal infections, the plasma levels of IL-10 correlate closely with the levels of meningococcal LPS (Table 3 ). 111 High levels of IL-10 are detected in serum collected from patients with fulminant meningococcal septicemia. 93, 111, [118] [119] [120] The highest levels were found in non-surviving patients. 93, 111, [118] [119] [120] The release of IL-10 is compartmentalized. 93, 105, 119 Patients with distinct meningitis reveal high levels in CSF and low in plasma, whereas the opposite pattern is present in patients with meningococcal septic shock. 93, 105 Plasma and CSF levels of IL-10 are rapidly down-regulated following antibiotic treatment and declining LPS levels. 105, 111, 118, 119 Plasma from patients with fulminant meningococcal septicemia has a de-activating effect on normal human monocytes stimulated by LPS. 111 Immunoprecipitation of the high IL-10 levels restored the monocyte activating capacity of the patients' plasma, leading to massive synthesis of TNF-α and IL-6, and generation of tissue factor based procoagulant activity. 111 Thus, IL-10 may have a crucial role in protecting the host from rapid 'overactivation' of circulating monocytes during episodes of human endotoxinemia. Other mechanisms leading to post-translational down-regulation of cytokine production in blood cells are also operative during and after meningococcal septic shock. 121 
Interleukin-12
IL-12 is a heterodimeric 70 kDa protein consisting of two peptide subunits p40 and p35. 122 More p40 than bioactive IL-12 is synthesized upon stimulation. p40 may have a separate regulatory role. IL-12 induces production of IFN-γ in T-cells and natural killer (NK) cells. p40 levels in plasma are significantly higher in non-survivors of meningococcal septic shock than in survivors. 123 IL-12 was detected in the plasma of only 20% of 46 patients with septic shock and purpura, and only 11% of the patients had both IL-12 and IFN-γ. 123 Among 28 patients with meningitis caused by N. meningitidis or H. influenzae, IL-12 and IFN-γ were detectable in CSF in 7% and 46%, respectively. 124 Bioactive IL-12 appears not to play a major role in meningococcal septic shock or meningitis.
Interferon-γ
Circulating IFN-γ was detected in one study of experimental E. coli endotoxinemia in man. 125 A second study using a much lower dose of E. coli LPS did not induced detectable IFN-γ. 126 Low levels of IFN-γ were present in a few patients with the most severe clinical presentation in the collaborative French-Swich meningococcal septic shock study (J5-study). 127 In a second study, IFN-γ levels > 400 pg/ml were not detected in any of the 79 patients studied. 100 Twelve (29%) of 41 Dutch children with meningococcal septic shock had IFN-γ levels > 2 pg/ml. 123 In 61 patients with meningococcal infections, IFN-γ (detection limit 0.03 IU/ml) was present at very low levels in 24 (39%); the median level was < 0.5 IU/ml (Bjerre A, unpublished data). Of 26 patients with fulminant septicemia, 16 (62%) had detectable levels versus 8 (23%) of 35 patients with meningitis or mild meningococcemia. Low levels of IFN-γ were present in plasmas with high levels of LPS. However, there was not a dose-response relationship as observed for many other cytokines (Bjerre A, unpublished results). IFN-γ appears not to play a major role in meningococcal septic shock.
Transforming growth factor-β TGF-β has a strong monocyte de-activating effect. 128 TGF-β was not detected in any of 10 meningococcal septic shock plasma samples that had a strong de-activating effect on normal human monocytes. 111
LPS AND ACTIVATION OF THE PLASMA CASCADE
SYSTEMS
If 2-4 ng/kg body weight of purified E. coli LPS is injected as a bolus into healthy young volunteers, the coagulation and the fibrinolytic systems are activated. 129, 130 The complement system is not activated in the same experiment. 129 In meningococcal infection, the coagulation, the fibrinolytic, the kallikrein-kinin, and the complement systems are all activated. 12, 17, 131 The degree of activation is related to clinical severity and LPS levels in the circulation. 12, 17, 131 
LPS and the complement system
Complement activation contributes to the development of septic shock in primate models. 132 The degree of complement activation is closely associated with both the circulating levels of LPS and clinical severity in meningococcal infections ( Table 3) . [133] [134] [135] Non-surviving patients with persistent septic shock revealed the most massive complement activation as judged by complement activation products at C3 and C5b-9 levels and consumption of lysis inhibitors. [133] [134] [135] [136] Both the classical and the alternative pathways are activated. 134, 135 Longitudinal studies indicate that the levels of complement activation products remain high or increase, reaching maximum values 12-15 h after initiation of therapy. [133] [134] [135] This differs from the longitudinal pattern of circulating pro-and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-10) that decline immediately after the first dose of antibiotics is administered, in parallel with plasma levels of LPS. The rapidly declining plasma levels of LPS and the increasing complement activation that occur during the first 12-24 h after initiation of effective therapy suggests that activation mechanisms other than direct interaction of LPS and C1q, factor B or MBL contribute significantly to complement activation in these patients.
In vitro studies suggest that N. meningitidis LPSs are weak complement activators (Bjerre A et al., J Infect Dis 2002;  In press). Mechanisms other than high plasma levels of LPS may contribute to the massive complement activation observed during fulminant meningococcal septicemia. An altered endothelial surface, denuded of vital molecules and possibly exposing subendothelial structures, could contribute to complement activation and thrombus formation. 137 
LPS and the coagulation system
Activation of the extrinsic pathway of the coagulation system contributes to the lethal septic shock induced by E. coli in baboons. 138 Bolus injections of E. coli LPS in healthy volunteers activate coagulation through the extrinsic pathway, i.e. tissue factor and activated factor VII (VIIa) of the coagulation system. 129, 139, 140 In vitro experiments demonstrate that LPSs initiate transcription of LPS-responsive genes (among others, tissue factor) through the CD14-TLR-4-NF-κB pathway. 141, 142 Hemorrhagic skin lesions are the hallmark of systemic meningococcal disease. Multiple lesions with a diameter ≥10 mm are associated with fulminant meningoccoccal septicemia, high levels of LPS, and high mortality. 17, 143 The local skin hemorrhage is caused by thrombus formation in the dermal vessels. 17, 144, 145 Meningococci are present within the endothelial cells and can be cultured from a needle aspirate or biopsy up to 12 h after initiation of antibiotic therapy. 144, 146 Adherence of meningococci and subsequent intracellular transmigration may possibly alter the antithrombotic properties on the abluminal surface of the endothelial cells. Adherent leukocytes, releasing proteases and oxygen radicals at the endothelial surface may add to the local damage. 131 Whether tissue factor is locally up-regulated and contributes to the thrombus formation in the microvasculature is presently not known in humans.
High levels of plasma LPS are associated with disseminated intravascular coagulation (DIC) and fibrin formation in meningococcal infections. 17, 147 The severity of the coagulopathy is reflected in low levels of coagulation factors VII, X, V, prothrombin, fibrinogen, and platelets; all are consumed during the diffuse formation of microthrombi. 104, 120, 139, [148] [149] [150] [151] The natural coagulation inhibitors antithrombin and protein C are pathologically low, whereas levels of tissue factor pathway inhibitor (TFPI), which is released from the vessel wall, are high. 104, 120, [147] [148] [149] [150] [151] Recombinant activated protein C may have a therapeutic potential in fulminant meningococcal septicemia, since it has significantly reduced the case fatality rate in sepsis caused by other bacteria. 152 The rate of fibrin formation, as measured by plasma levels of fibrinopeptide A (half-life of 2-3 min), decreases immediately after antibiotic therapy is initiated. 147 However, the microcirculation is increasingly compromised with skin hemorrhages and vascular occlusion leading to gangrene. Surviving patients often require amputation of digits, hands, and feet in addition to extensive skin grafting.
LPS and fibrinolysis
Bolus injection of E. coli LPS into healthy volunteers upregulates tissue plasminogen activator. 130 Subsequently, fibrinolysis is inhibited due to release of plasminogen activator inhibitor-1 (PAI-1) from endothelial cells. 129, 130 The same sequence of events appears to occur in patients with fulminant meningococcal septicemia. Before hospital admission, active fibrinolysis has occurred. Large quantities of fibrin degradation products (FDP/Ddimers) are detectable in plasma on hospital admission. 104, 153 However, by this time, fibrinolysis is already markedly inhibited when evaluated by a functional assay. 154 This is presumably a consequence of PAI-1 being released from endothelial cells and possibly from platelets. 104, 153 Activation of coagulation and reduced fibrinolysis, combined with an altered endothelial surface, facilitate thrombus formation. PAI-1 in plasma declines rapidly in parallel with plasma LPS as soon as therapy is initiated. 153, 154 High levels of PAI-1 predict the development of persistent septic shock and fatal outcome. 104, 120, 153 The G4/G5 polymorphism in the promotor region of the PAI-1 gene is associated with high plasma levels of PAI-1 and increased mortality in meningococcal infections. 155 
LPS and the kallikrein-kinin system
Activation of the kallikrein-kinin system contributes to hypotension and lethality in E. coli-induced septic shock in baboons and is associated with septic shock in man. 156, 157 In meningococcal infections, prekallikrein and kallikrein inhibitor are significantly lower in shock patients with high plasma levels of LPS than in normotensive patients with low or undetectable LPS levels. 131 The levels of prekallikrein were negatively correlated to the levels of plasma LPS (Table  3) . 131 These results suggest that prekallikrein is massively converted to kallikrein by activated factor XII (Hageman factor) or some other protease in patients with fulminant meningococcal septicemia. Kallikrein cleaves off the nonapeptide bradykinin from high molecular weight kininogen. Kallikrein is neutralized by kallikrein inhibitor, which is consumed in meningococcal septic shock. 131 Bradykinin has a major impact on endothelial cells, inducing vasodilation and capillary leakage. Furthermore, in cell and animal experiments, bradykinin activates inducible NO synthase (iNOS). 157 The LPS-induced vasodilation in baboons can be avoided by pretreatment with an antibody blocking factor XIIa (activated Hageman factor). 156 The relative contributions of bradykinin and NO versus the plethora of other vasodilating principles generated in meningococcal septic shock are presently unknown. 158
LPS AND ACTIVATION OF BLOOD CELLS
LPS and neutrophil granulocyte activation
Patients with high levels of LPS and inflammatory mediators in plasma, developing septic shock, are usually leukopenic on hospital admission. 17 Non-survivors reveal lower leukocyte counts than survivors. 149 Patients without a compromised circulation and lower levels of LPS in plasma reveal a marked leukocytosis on admission. Leukopenia has for a long time been used as a marker of clinical severity in meningococcal infections. [159] [160] [161] The transient leukopenic phase, usually lasting < 12 h after admission in patients with meningococcal septic shock, presumably reflects margination, i.e. adherence of circulating neutrophils to endothelial cells. This adherence is mediated by up-regulation of various adhesion molecules on the neutrophils and endothelial cells. Experimental human E. coli endotoxinemia initiates leukopenia followed by leukocytosis and mobilization of a subset of young neutrophils from the bone marrow. 162 The leukopenic response is blocked if TNF-α is inhibited by a recombinant dimeric TNF receptor fusion protein. 163 The neutrophils marginate primarily in the lungs in E. coli-induced septic shock in baboons. 164 It is not known where the neutrophils marginate in man.
Concomitantly with margination, the neutrophils release elastase, other proteases, and presumably toxic oxygen radicals in close vicinity to the endothelial cell surface. The highest levels of elastase-antiprotease complexes may be detected during the most leukopenic phase. 131 The elastase-antiprotease complexes decline while the levels of young neutrophils in the peripheral blood increase (Brandtzaeg P, unpublished results) . Plasma levels of neutrophil specific elastase-antiprotease complexes correlate with the plasma levels of LPS in meningococcal infections (Table 4 ). 131 Calprotectin, another neutrophil-associated protein with antimicrobial properties, is also massively released in patients with fulminant meningococcal septicemia. 165 Model studies using whole blood and live meningococci indicate that LPSs augment neutrophil activation. 166 The increased neutrophil activation was blocked by rBPI 21 , a 21 kDa positively charged recombinant protein fragment of bactericidal/permeability increasing protein (BPI), which binds to, and neutralizes the biological effects of, lipid A. 166 The transient leukopenia in patients with fulminant meningococcal septicemia is followed by leukocytosis. Young neutrophils are massively released from the bone marrow; this is reflected in a high percentage of band forms in peripheral blood. High plasma levels of granulocyte colony stimulating factor (G-CSF) and granulocyte monocyte colony stimulating factor (GM-CSF) presumably contribute to the recruitment of the neutrophils. 167 Plasma levels of G-CSF and GM-CSF collected on admission are quantitatively related to the levels of LPS (Brandtzaeg P, unpublished results). Interestingly, bioactive cytidine deaminase, an enzyme which is abundantly present in neutrophils, is released into the circulation during massive meningococcal endotoxinemia. 168 Possibly, cytidine deaminase may form part of a negative feed-back loop, antagonizing the effects of G-CSF and GM-CSF on neutrophils and bone marrow progenitor cells. 168 
LPS and monocytes
Monocytes isolated from meningococcal septic shock patients are de-activated when tested ex vivo owing to the high levels of IL-10 and other mechanisms. 111, 121 The sup-pression of certain monocyte functions such as production of tissue factor (TF) is clearly not completely suppressed during extreme endotoxinemia. 111 Lysed monocytes isolated from patients with fulminant meningococcal septicemia reveal a significant up-regulation of procoagulant activity compared with monocytes isolated from patients with less severe meningococcal infections. 169 Serial measurements in isolated mononuclear cells indicated a rapid down-regulation of TF synthesis after treatment was started. 169 Plasma collected from patients with fulminant meningococcal septicemia contain monocyte fragments with procoagulant, i.e. TF, activity. 170 
LPS and platelets
The platelets are massively consumed in patients with fulminant meningococcal septicemia due to the on-going coagulation. The numbers decline to low levels during the first 24-36 h of the disease and remain low for many days. 104, 171 Thrombopoietin increases in plasma without a concomitant rise in the platelet levels. 172 This may indicate a persistently high level of platelet consumption related to the damaged endothelium or to altered maturation of the megakaryocytes with reduced release of platelets in the bone marrow. 172 
LPS and vasoactive intestinal peptide
Vasoactive intestinal peptide (VIP) has a vasodilating effect and is up-regulated in patients with meningococcal septic shock with high levels of plasma LPS. 173 VIP and LPS levels in plasma were positively correlated in one study (Table 4 ). 173 The levels of VIP declined and reached normal levels a few hours after the initiation of antibiotic and fluid therapy. 173 Animal experiments suggest that during septic shock VIP is principally released from the intestines. 174 
LPS and organ dysfunction
The main organ systems affected during meningococcal septicemia are the cardiovascular system, kidneys, adrenals, lungs and skin. The pathophysiology of these changes has recently been extensively reviewed. 12, 17, [21] [22] [23] 
GENETIC POLYMORPHISM, DEVELOPMENT OF
INVASIVE INFECTION AND OUTCOME
Genetic polymorphism influences the levels of mannanbinding lectin and the function of immunoglobulin receptors IIa (CD32) and IIIb (CD16b) on neutrophils, monocytes and macrophages. 62, 175, 176 It has been related to the propensity to contract meningococcal infections. 62 The allelic variation R/R 131 of Fc gamma IIa receptor was detected significantly more frequently among Dutch children with meningococcal septic shock than in the normal population. 175 Polymorphism in the promotor region of the PAI-1 gene (4G/4G or 4G/5G) coding for increased production has been associated with the development of shock and fatal outcome in meningococcal infections. 155, 177 High plasma levels of TNF-α are associated with meningococcal septic shock and lethal outcome. 93, 100, 102 Polymorphism in the promotor region of the TNF-α gene (G to A at position -308) may increase the TNF-α level. This polymorphism was associated with an increased risk of death in a British study; however, it was not confirmed in a Dutch study. 178, 179 Fatality caused by shock and multiple organ failure may be related to a genetically-determined cytokine response pattern. Family members of non-surviving meningococcal patients produced less TNF-α and more IL-10 than did the family members of survivors when studied with a whole blood assay stimulated with E. coli LPS. 179 The levels of IL-10 did not correlate with the levels of TNF-α in this assay. 180 These observations suggest that a complex interplay exists between the intruding meningococci, the levels of LPS and other inflammation inducing molecules and the host's genetically determined reaction to these molecules as they accumulate in the circulation or CSF.
STRATEGIES TO NEUTRALIZE N. MENINGITIDIS LPS
Clinical trials aimed to neutralize N. meningitidis LPS Three randomized, double-blind controlled clinical trials have been conducted during the last decade. 127, 181, 182 None of the trials could document a significant survival benefit in the treatment group (Table 5 & 6) . The J5 study enrolled 73 children to evaluate the anti-endotoxin effect of human serum obtained by immunizing healthy volunteers with the rough E. coli J5 mutant that expresses the core structure of LPS (the J5 study). 127 The mortality (25%) was lower in the treatment group than the control group (36%), but the difference was not statistically significant. The second study enrolled 269 children and young adults. 181 The treatment group received HA-1A, a human and mouse chimeric monoclonal IgM antibody that cross-reacts with LPS obtained from different bacteria. The 28 days' survival was 18% in the treatment group and 27% in the control group, again not a statistically significant difference. The third study enrolled 393 children and young adults of whom 191 received rBPI 21 , the 21 kDa N-terminal fragment of bactericidal/permeability increasing protein, which neutralizes the biological effects of lipid A. 182 Fourteen patients (7.4%) died in the treatment group versus 20 (8.7%) in the control group (P > 0.05; Table 6 ). So far, anti-LPS strategies have not increased the chances of survival significantly in meningococcal septic shock. However, treatment with rBPI 21 reduced the severe complications of fulminant meningococcal septicemia, i.e. amputations and extensive skin grafting. 182 In no trial did the treatment group achieve a statistically significant reduction in mortality.
Why did the anti-LPS strategy not reduce the case fatality rate in meningococcal septic shock?
The J5 antisera did not have significantly more cross-reacting antibodies against core (anti-Re LPS) or lipid A than sera collected before immunizing. 183 The HA-1A IgM monoclonal antibody did not neutralize the biological effects of meningococcal LPS. 184 The clearance rate of LPS in the group receiving HA-1A was similar to that of the control group. 181 Thus, HA-1A did not facilitate removal of biological active N. meningitidis LPS from the circulation. In the rBPI 21 trial, the case fatality rate was much lower than expected suggesting that the general care given to the patients was optimal and possibly that less severe cases were enrolled in both groups. 182 A much larger number of patients had to be included in the study to document a moderate beneficial effect of rBPI 21 . Furthermore, rBPI 21 was given 6 h (mean) after antibiotic treatment was initiated. 182 Most of the circulating meningococcal LPS had presumably already been removed from the circulation by natural clearance mechanisms, reducing the potential beneficial effect of the drug. 17, 18, 93, 185 Important factors that must be considered in anti N. meningitidis LPS trials
First, meningococcal LPSs decline immediately after the first dose of an effective antibiotic is initiated. 17, 18, 93 The half-life of native meningococcal LPS is 1-3 h as determined by the LAL assay. 17, 18, 93 Thus, an anti-LPS therapy has to be applied simultaneously with, or immediately after, the antibiotic therapy starts to be most effective. 185 Second, the concentrations of most blood pro-and antiinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10) and other important mediators of inflammation which are released into the circulation decline in parallel with LPS. In fact, the only major plasma inflammatory mediator system which has been documented to increase or persist at a high level during the first 12 h of antibiotic and fluid treatment is the complement system. [133] [134] [135] Thus, early antibiotic treatment stops further escalation of a variety of inflammatory mediators. The natural elimination of these mediators results in rapidly declining levels without specific antagonistic treatment. Third, the case fatality rate in patients with meningococcal septic shock increases from 0% to > 80% when the levels of plasma LPS increase from 10 EU/ml to 100 EU/ml, a 10-fold increase. Between these levels, there is a dose-dependent increase in mortality. A strategy to stop the rapidly escalating LPS levels in plasma, as early as possible, is mandatory. Presently, this goal can only be reached by treating suspect patients with antibiotics as early as possible. 185 
Will neutralization of N. meningitidis lipid A have a major beneficial role in meningococcal infections?
From what has been mentioned above, it is clear that LPS (and in particular lipid A) is a key molecule in the pathophysiology of meningococcal infections. Thus, it appears logical to pursue an effective anti-N. meningitidis lipid A therapy. However, the therapeutic effect of such a principle may be limited. The endothelial and smooth muscle cells in the vessels and the cardiomyocytes are already intensely activated as a consequence of the mediator 'storm' already generated by lipid A and other bacterial components. Whether a faster clearance of bioactive lipid A from plasma really will alter the disease course in fulminant meningococcal septicemia remains to be documented. Strategies to normalize the function of the 'overactivated' target cells may possibly be more beneficial.
CONCLUDING REMARKS
Today we know that LPS is a major, but not the only, inflammatory-inducing principle harbored in the outer membrane of N. meningitidis. How meningococci circumvent the host's immune system and generate extraordinarily high levels of LPS in the circulation in few hours is presently not understood. The relationship between LPS and the observed pathophysiology has been more extensively studied and is presently better characterized in meningococcal infections than in any other human Gram-negative infection. 12, 17 A quantitative relationship exists between bioactive meningococcal LPS and various mediator systems triggered directly or indirectly by LPS. At concentrations > 10 7 CFU/ml, other outer membrane molecules may contribute to the inflammation. [26] [27] [28] [29] [30] The degree of activation of these mediator systems is reflected in the case fatality rate which increases from 0% to > 80% with a 10-fold increase in plasma LPS from 10 EU/ml to 100 EU/ml. Effective antibiotic treatment results in an immediate decline of LPS and many key inflammatory mediators in plasma. Early antibiotic treatment is mandatory to stop further LPS production before it reaches a 100% fatal level. Meningococcal septic shock plasma has a de-activating effect on human monocytes and presumably on other blood cells owing to high levels of IL-10. So far, three different anti-LPS strategies have been ineffective in reducing mortality. However, the truncated bactericidal/permeability increasing protein (rBPI 21 ) reduced the severe complications. This suggests that neutralization of meningococcal lipid A in the circulation is beneficial to the patients. If new anti-LPS principles are going to be explored in the future, they should be applied as early as possible, ideally together with the first dose of antibiotics.
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